The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Genetic Alterations in the Phosphatidylinositol-3 Kinase/Akt Pathway in Thyroid Cancer
Open accessAbstract
BACKGROUND: Aberrant activation of the phosphatidylinositol-3 kinase (PI3K)/Akt pathway plays a fundamental role in thyroid tumorigenesis, particularly in follicular thyroid cancer (FTC) and aggressive thyroid cancer, such as anaplastic thyroid cancer (ATC). As the drivers of this process, many genetic alterations activating the PI3K/Akt pathway have been identified in thyroid cancer in recent years. SUMMARY: This review summarizes the current knowledge on major genetic alterations in the PI3K/Akt pathway. These include PIK3CA mutations and genomic amplification/copy gain, Ras mutations, PTEN mutations, RET/PTC and PPARgamma/Pax8 rearrangements, as well as amplification/copy gain of PIK3CB, PDK1, Akt, and various receptor tyrosine kinase genes. Most of these genetic alterations are particularly common in FTC and many of them are even more common in ATC; they are generally less common in papillary thyroid cancer (PTC), in which the MAP kinase (MAPK) pathway activated by the BRAF mutation instead plays a major role. Methylation and, thus, epigenetic silencing of PTEN, a major negative regulator of the PI3K/Akt pathway, occurs in close association with activating genetic alterations of the PI3K/Akt pathway, constituting a unique self-enhancement mechanism for this pathway. Many of these genetic alterations are mutually exclusive in differentiated thyroid tumors, but with increasing concurrence from benign tumors to FTC to ATC. RET/PTC, Ras, and receptor tyrosine kinase could dually activate the PI3K/Akt and MAPK pathways. Most cases of ATC harbor genetic alterations in these genes or other genetic combinations that can activate both pathways. It is proposed that genetic alterations in the PI3K/Akt pathway promote thyroid cell transformation to FTC and that genetic alterations in the MAPK pathway promote cell transformation to PTC; accumulation of multiple genetic alterations that can activate both pathways promotes thyroid cancer aggressiveness and progression to ATC. CONCLUSIONS: Genetic alterations are common in the PI3K/Akt pathway in thyroid cancer and play a fundamental role in the tumorigenesis and progression of this cancer. This provides a strong basis for the emerging development of novel genetic-based diagnostic, prognostic, and therapeutic strategies for thyroid cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Targeting the phosphoinositide 3-kinase pathway in cancer
Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,721
PI3K/Akt signalling pathway and cancer
Vara, J. Á. F., Casado, E., de Castro, J., Cejas, P., Belda-Iniesta, C., & González-Barón, M. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.07.007 · Cited by 2,443
Cantley, L. C., & Neel, B. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4240 · Cited by 2,006
Phosphatidylinositol-3-OH kinase direct target of Ras
Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., & Downward, J. (1994) · Nature · doi:10.1038/370527a0 · Cited by 1,954
RAS oncogenes: the first 30 years
Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902 · cited 1×
“Mutations in the three types of Ras genes—H-Ras, K-Ras, and N-Ras—are commonly seen in human cancers with a frequency, on average, of 30% (34,35).”
BRAF mutation in thyroid cancer
Xing, M. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.0978 · Cited by 1,300
Self-citationThe PI3K Pathway As Drug Target in Human Cancer
Courtney, K. D., Corcoran, R. B., & Engelman, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3641 · Cited by 1,237
BrafV600E cooperates with Pten loss to induce metastatic melanoma
Dankort, D., Curley, D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., Damsky Jr, W. E., You, M. J., DePinho, R. A., McMahon, M., & Bosenberg, M. (2009) · Nature Genetics · doi:10.1038/ng.356 · Cited by 1,189
PIK3CA is implicated as an oncogene in ovarian cancer
Shayesteh, L., Lu, Y., Kuo, W.-L., Baldocchi, R., Godfrey, T., Collins, C., Pinkel, D., Powell, B., Mills, G. B., & Gray, J. W. (1999) · Nature Genetics · doi:10.1038/5042 · Cited by 1,155
Xing, M. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0007 · Cited by 983
Self-citationThe Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway
Sansal, I., & Sellers, W. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.141 · Cited by 921
Pathogenetic mechanisms in thyroid follicular-cell neoplasia
Kondo, T., Ezzat, S., & Asa, S. L. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1836 · Cited by 893
PAX8-PPAR γ 1 Fusion in Oncogene Human Thyroid Carcinoma
Kroll, T. G., Sarraf, P., Pecciarini, L., Chen, C.-J., Mueller, E., Spiegelman, B. M., & Fletcher, J. A. (2000) · Science · doi:10.1126/science.289.5483.1357 · Cited by 784
Molecular Testing for Mutations in Improving the Fine-Needle Aspiration Diagnosis of Thyroid Nodules
Nikiforov, Y. E., Steward, D. L., Robinson-Smith, T. M., Haugen, B. R., Klopper, J. P., Zhu, Z., Fagin, J. A., Falciglia, M., Weber, K., & Nikiforova, M. N. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0247 · Cited by 711
Targeting the mTOR Signaling Network for Cancer Therapy
Meric-Bernstam, F., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0766 · Cited by 639
Haigis, K. M., Kendall, K. R., Wang, Y., Cheung, A., Haigis, M. C., Glickman, J. N., Niwa-Kawakita, M., Sweet-Cordero, A., Sebolt-Leopold, J., Shannon, K. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.115 · Cited by 610
Mutations in a signalling pathway
Parsons, D. W., Wang, T.-L., Samuels, Y., Bardelli, A., Cummins, J. M., DeLong, L., Silliman, N., Ptak, J., Szabo, S., Willson, J. K. V., et al. (2005) · Nature · doi:10.1038/436792a · Cited by 599
Binding of Ras to Phosphoinositide 3-Kinase p110α Is Required for Ras- Driven Tumorigenesis in Mice
Gupta, S., Ramjaun, A. R., Haiko, P., Wang, Y., Warne, P. H., Nicke, B., Nye, E., Stamp, G., Alitalo, K., & Downward, J. (2007) · Cell · doi:10.1016/j.cell.2007.03.051 · Cited by 589
Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation.
Rodriguez-Viciana, P., Warne, P. H., Vanhaesebroeck, B., Waterfield, M. D., & Downward, J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00602.x · Cited by 566
Ricarte-Filho, J. C., Ryder, M., Chitale, D. A., Rivera, M., Heguy, A., Ladanyi, M., Janakiraman, M., Solit, D., Knauf, J. A., Tuttle, R. M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0727 · Cited by 529
PIK3CA as an oncogene in cervical cancer
Ma, Y.-Y., Wei, S.-J., Lin, Y.-C., Lung, J.-C., Chang, T.-C., Whang-Peng, J., Liu, J. M., Yang, D.-M., Yang, W. K., & Shen, C.-Y. (2000) · Oncogene · doi:10.1038/sj.onc.1203597 · Cited by 434
Hou, P., Liu, D., Shan, Y., Hu, S., Studeman, K., Condouris, S., Wang, Y., Trink, A., El-Naggar, A. K., Tallini, G., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1125 · Cited by 418
Self-citationHigh prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xu, X., Quiros, R. M., Gattuso, P., Ain, K. B., & Prinz, R. A. (2003) · PubMed · Cited by 415
Liu, Z., Hou, P., Ji, M., Guan, H., Studeman, K., Jensen, K., Vasko, V., El-Naggar, A. K., & Xing, M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0273 · Cited by 390
Self-citationZhu, Z., Gandhi, M., Nikiforova, M. N., Fischer, A. H., & Nikiforov, Y. E. (2003) · American Journal of Clinical Pathology · doi:10.1309/nd8d-9laj-trct-g6qd · Cited by 371
ras Mutations Are Associated With Aggressive Tumor Phenotypes and Poor Prognosis in Thyroid Cancer
Garcia-Rostan, G., Zhao, H., Camp, R. L., Pollan, M., Herrero, A., Pardo, J., Wu, R., Carcangiu, M. L., Costa, J., & Tallini, G. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.130 · Cited by 368
Zhu, Z., Gandhi, M., Nikiforova, M. N., Fischer, A. H., & Nikiforov, Y. E. (2003) · American Journal of Clinical Pathology · doi:10.1309/nd8d9lajtrctg6qd · Cited by 355
Mutation of the PIK3CA Gene in Anaplastic Thyroid Cancer
García-Rostán, G., Costa, A. M., Pereira-Castro, I., Salvatore, G., Hernandez, R., Hermsem, M. J. A., Herrero, A., Fusco, A., Cameselle-Teijeiro, J., & Santoro, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4259 · Cited by 338
Physiological roles of PKB/Akt isoforms in development and disease
Dummler, B., & Hemmings, B. A. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350231 · Cited by 316
Cantara, S., Capezzone, M., Marchisotta, S., Capuano, S., Busonero, G., Toti, P., Di Santo, A., Caruso, G., Carli, A. F., Brilli, L., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2103 · Cited by 315
Specific Pattern of RAS Oncogene Mutations in Follicular Thyroid Tumors
Vasko, V., Ferrand, M., Di Cristofaro, J., Carayon, P., Henry, J. F., & de Micco, C. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021186 · Cited by 310
Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors.
Dahia, P. L. M., Marsh, D. J., Zheng, Z., Zedenius, J., Komminoth, P., Frisk, T., Wallin, G., Parsons, R. E., Longy, M., Larsson, C., et al. (1997) · PubMed · Cited by 306
Overexpression and overactivation of Akt in thyroid carcinoma.
Ringel, M. D., Hayre, N., Saito, J., Saunier, B., Schuppert, F., Burch, H., Bernet, V., Burman, K. D., Kohn, L. D., & Saji, M. (2001) · PubMed · Cited by 297
Ried, T., Heselmeyer-Haddad, K., Blegen, H., Schr�ck, E., & Auer, G. (1999) · Genes, Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199907)25:3<195::aid-gcc1>3.0.co;2-8 · Cited by 285
Elisei, R., Romei, C., Vorontsova, T., Cosci, B., Veremeychik, V., Kuchinskaya, E., Basolo, F., Demidchik, E. P., Miccoli, P., Pinchera, A., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.7.7678 · Cited by 275
Expression of the RET/PTC Fusion Gene as a Marker for Papillary Carcinoma in Hashimoto's Thyroiditis
Wirtschafter, A., Schmidt, R., Rosen, D., Kundu, N., Santoro, M., Fusco, A., Multhaupt, H., Atkins, J. P., Rosen, M. R., Keane, W. M., et al. (1997) · The Laryngoscope · doi:10.1097/00005537-199701000-00019 · Cited by 257
Ohori, N. P., Nikiforova, M. N., Schoedel, K. E., LeBeau, S. O., Hodak, S. P., Seethala, R. R., Carty, S. E., Ogilvie, J. B., Yip, L., & Nikiforov, Y. E. (2010) · Cancer Cytopathology · doi:10.1002/cncy.20063 · Cited by 254
RET/PTC Rearrangements and BRAF Mutations in Thyroid Tumorigenesis
Ciampi, R., & Nikiforov, Y. E. (2007) · Endocrinology · doi:10.1210/en.2006-0921 · Cited by 241
Segouffin-Cariou, C., & Billaud, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.5.3568 · Cited by 223
Hayashi, H., Ichihara, M., Iwashita, T., Murakami, H., Shimono, Y., Kawai, K., Kurokawa, K., Murakumo, Y., Imai, T., Funahashi, H., et al. (2000) · Oncogene · doi:10.1038/sj.onc.1203799 · Cited by 223
Vasko, V, Saji, M., Hardy, E., Kruhlak, M., Larin, A., Savchenko, V, Miyakawa, M., Isozaki, O., Murakami, H., Tsushima, T., et al. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2003.015339 · Cited by 211
Zhu, Z., Ciampi, R., Nikiforova, M. N., Gandhi, M., & Nikiforov, Y. E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1006 · Cited by 209
Santarpia, L., El-Naggar, A. K., Cote, G. J., Myers, J. N., & Sherman, S. I. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1076 · Cited by 208
Volante, M., Rapa, I., Gandhi, M., Bussolati, G., Giachino, D., Papotti, M., & Nikiforov, Y. E. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1233 · Cited by 193
Uncommon Mutation, but Common Amplifications, of the PIK3CA Gene in Thyroid Tumors
Wu, G., Mambo, E., Guo, Z., Hu, S., Huang, X., Gollin, S. M., Trink, B., Ladenson, P. W., Sidransky, D., & Xing, M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2281 · Cited by 191
Self-citationThe PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors
Saji, M., & Ringel, M. D. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.10.016 · Cited by 190
RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture
Santoro, M., Melillo, R. M., & Fusco, A. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02289 · Cited by 190
Gene Methylation in Thyroid Tumorigenesis
Xing, M. (2007) · Endocrinology · doi:10.1210/en.2006-0927 · Cited by 174
Self-citationWang, Y., Hou, P., Yu, H., Wang, W., Ji, M., Zhao, S., Yan, S., Sun, X., Liu, D., Shi, B., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2019 · Cited by 172
Self-citationAbubaker, J., Jehan, Z., Bavi, P., Sultana, M., Al-Harbi, S., Ibrahim, M., Al-Nuaim, A., Ahmed, M., Amin, T., Al-Fehaily, M., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1717 · Cited by 169
PTEN Promoter Methylation in Sporadic Thyroid Carcinomas
Álvarez-Núñez, F., Bussaglia, E., Mauricio, D., Ybarra, J., Vilar, M., Lerma, E., de Leiva, A., & Matías‐Guiu, X. (2006) · Thyroid · doi:10.1089/thy.2006.16.17 · Cited by 164
Bertelsen, B. I., Steine, S. J., Sandvei, R., Molven, A., & Lærum, O. D. (2005) · International Journal of Cancer · doi:10.1002/ijc.21461 · Cited by 153
Woenckhaus, J., Steger, K., Werner, E., Fenic, I., Gamerdinger, U., Dreyer, T., & Stahl, U. (2002) · The Journal of Pathology · doi:10.1002/path.1207 · Cited by 152
Gustafson, S. L., Zbuk, K. M., Scacheri, C., & Eng, C. (2007) · Seminars in Oncology · doi:10.1053/j.seminoncol.2007.07.009 · Cited by 148
Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone β receptor
Furuya, F., Hanover, J. A., & Cheng, S.-Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510849103 · Cited by 147
Bruni, P., Boccia, A. S., Baldassarre, G., Trapasso, F., Santoro, M., Chiappetta, G., Fusco, A., & Viglietto, G. (2000) · Oncogene · doi:10.1038/sj.onc.1203633 · Cited by 145
Elisei, R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.7.3211 · Cited by 137
Hou, P., Ji, M., & Xing, M. (2008) · Cancer · doi:10.1002/cncr.23869 · Cited by 136
Self-citationHigh Rate of BRAF and RET/PTC Dual Mutations Associated with Recurrent Papillary Thyroid Carcinoma
Henderson, Y. C., Shellenberger, T. D., Williams, M. D., El‐Naggar, A. K., Fredrick, M. J., Cieply, K. M., & Clayman, G. L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0933 · Cited by 132
Detection of retTPC/PTC transcripts in thyroid adenomas and adenomatous goiter by an RT-PCR method.
Ishizaka, Y., Kobayashi, S. S., Ushijima, T., Hirohashi, S., Sugimura, T., & Nagao, M. (1991) · PubMed · Cited by 131
Costa, Â. M., Herrero, A., Fresno, M., Heymann, J. J., Alvarez, J. A., Cameselle‐Teijeiro, J., & García‐Rostán, G. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03077.x · Cited by 129
Somatic mutations of thePTEN tumor suppressor gene in sporadic follicular thyroid tumors
Halachmi, N., Halachmi, S., Evron, E., Cairns, P., Okami, K., Saji, M., Westra, W. H., Zeiger, M. A., Jen, J., & Sidransky, D. (1998) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199811)23:3<239::aid-gcc5>3.0.co;2-2 · Cited by 129
Miller, K. A., Yeager, N., Baker, K., Liao, X.-H., Refetoff, S., & Cristofano, A. D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0024 · Cited by 129
Vasko, V. V., Hu, S., Wu, G., Xing, J. C., Ларін, О. С., Savchenko, V., Trink, B., & Xing, M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2353 · Cited by 121
Self-citationSilencing of the PTEN tumor‐suppressor gene in anaplastic thyroid cancer
Frisk, T., Foukakis, T., Dwight, T., Lundberg, J., Höög, A., Wallin, G., Eng, C., Zedenius, J., & Larsson, C. (2002) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10098 · Cited by 107
Do Benign Thyroid Nodules Have Malignant Potential? An Evidence‐Based Review
Arora, N., Scognamiglio, T., Zhu, B., & Fahey, T. J. (2008) · World Journal of Surgery · doi:10.1007/s00268-008-9484-1 · Cited by 105
Activation of PPARγ increases PTEN expression in pancreatic cancer cells
Farrow, B. J., & Evers, B. M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02983-2 · Cited by 102
Schagdarsurengin, U., Gimm, O., Dralle, H., Hoang‐Vu, C., & Dammann, R. (2006) · Thyroid · doi:10.1089/thy.2006.16.633 · Cited by 101
Intragenic Mutations in Thyroid Cancer
Sobrinho-Simões, M. A., Máximo, V., Rocha, A. S., Trovisco, V., Castro, P., Preto, A., Lima, J. P., & Soares, P. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.02.004 · Cited by 101
The role of the PAX8/PPARγ fusion oncogene in the pathogenesis of follicular thyroid cancer
Eberhardt, N. L., Grebe, S. K. G., McIver, B., et al. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.10.013 · Cited by 100
Salerno, P., Falco, V. D., Tamburrino, A., Nappi, T. C., Vecchio, G., Schweppe, R. E., Bollag, G. E., Santoro, M. M., & Salvatore, G. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0373 · Cited by 98
RAS: Target for Cancer Therapy
Saxena, N., Lahiri, S. S., Hambarde, S., & Tripathi, R. P. (2008) · Cancer Investigation · doi:10.1080/07357900802087275 · Cited by 94
Liu, D., Hou, P., Liu, Z., Wu, G., & Xing, M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1077 · Cited by 88
Self-citationCastellone, M. D., Falco, V. D., Rao, D. M., Bellelli, R., Muthu, M., Basolo, F., Fusco, A., Gutkind, J. S., & Santoro, M. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1982 · Cited by 88
Jin, N. Y., Jiang, T., Rosen, D. M., Nelkin, B. D., & Ball, D. W. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0662 · Cited by 78
Recent Advances in Molecular Biology of Thyroid Cancer and Their Clinical Implications
Xing, M. (2008) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2008.07.001 · Cited by 77
Self-citationLiu, D., Xing, J., Trink, B., & Xing, M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25304 · Cited by 61
Self-citationIn vitro reconstruction of tumour initiation in a human epithelium.
Bond, J. A., Wyllie, F. S., Rowson, J., Radulescu, A., & Wynford‐Thomas, D. (1994) · PubMed · Cited by 61
Kim, D. W., Hwang, J. H., Suh, J. M., Kim, H., Song, J. H., Hwang, E. S., Hwang, I. Y., Park, K. C., Chung, H. K., Kim, J., et al. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0402 · Cited by 50
Miyagi, E., Braga‐Basaria, M., Hardy, E., Vasko, V. V., Burman, K. D., Jhiang, S. M., Saji, M., & Ringel, M. D. (2004) · Molecular Carcinogenesis · doi:10.1002/mc.20042 · Cited by 50
Gire, V., & Wynford‐Thomas, D. (2000) · Oncogene · doi:10.1038/sj.onc.1203399 · Cited by 49
Fendri, A., Khabir, A., Mnejja, W., Sellami‐Boudawara, T., Daoud, J., Frikha, M., Ghorbel, A., Gargouri, A. F., & Mokdad‐Gargouri, R. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01292.x · Cited by 45
Molecular biology of thyroid cancer initiation
Riesco‐Eizaguirre, G., & Santisteban, P. (2007) · Clinical & Translational Oncology · doi:10.1007/s12094-007-0125-1 · Cited by 27
Genetic-Targeted Therapy of Thyroid Cancer: A Real Promise
Xing, M. (2009) · Thyroid · doi:10.1089/thy.2009.1583 · Cited by 10
Self-citationMolecular Biology of Thyroid Cancer
Chien, W., & Koeffler, H. P. (2011) · Endocrine updates · doi:10.1007/978-1-4614-0875-8_2 · Cited by 10
Cited by
Progress in molecular-based management of differentiated thyroid cancer
Xing, M., Haugen, B. R., & Schlumberger, M. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60109-9 · Cited by 573
Self-citationTERT promoter mutations in thyroid cancer
Liu, R., & Xing, M. (2016) · Endocrine-Related Cancer · doi:10.1530/erc-15-0533 · Cited by 441
Self-citationModulation of inflammation by autophagy: Consequences for human disease
Netea-Maier, R. T., Plantinga, T. S., van de Veerdonk, F. L., Smit, J. W., & Netea, M. G. (2016) · Autophagy · doi:10.1080/15548627.2015.1071759 · Cited by 349
ß-catenin signaling is required for RAS-driven thyroid cancer through PI3K activation
Sastre-Perona, A., Riesco-Eizaguirre, G., Zaballos, M. A., & Santisteban, P. (2016) · Oncotarget · doi:10.18632/oncotarget.10356 · Cited by 51
ABI3, a component of the WAVE2 complex, is potentially regulated by PI3K/AKT pathway
Moraes, L., Zanchin, N. I. T., & Cerutti, J. M. (2017) · Oncotarget · doi:10.18632/oncotarget.18840 · Cited by 22
Metadata
- Authors
- Xing, M.
- Venue
- Thyroid
- Publisher
- SAGE Publications
- Published
- 2010-07
- Volume
- 20
- Issue
- 7
- Pages
- 697-706
- ISSN
- 1050-7256 (ISSN-L)
- 1557-9077
- OpenAlex
- W2119156172
- Cited by
- 305
- References
- 87
- FWCI
- 15.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
